Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 19, 2011
Oct 14, 2011 07:00:00 (ET)
HONG KONG, Oct. 14, 2011 /PRNewswire via COMTEX/ -- China Cord Blood Corporation (CO, Trade ) ("CCBC" or "the Company"), the first and largest cord blood banking operator in China, today announced that the Company will hold its annual general meeting of shareholders at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 19, 2011 (8:00 a.m. U.S. Eastern Time on December 19)(8:2011).
Shareholders of record as of November 9, 2011 will be entitled to receive notice of and vote at the annual general meeting. China Cord Blood Corporation filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended March 31, 2011, with the U.S. Securities and Exchange Commission (the "SEC") on September 28, 2011. CCBC's annual report on Form 20-F can be accessed at the Investor Center section of the Company's website at http://www.chinacordbloodcorp.com , as well as on the SEC's website at http://www.sec.gov . Shareholders may request a meeting notice, proxy statement and hard copy of the annual report on Form 20-F free of charge by contacting ir@chinacordbloodcorp.com.
China Cord Blood Corporation Files Its Annual Report on Form 20-F
http://ih.advfn.com/p.php?pid=nmona&article=49342453&symbol=CO
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company has filed with the U.S. Securities and Exchange Commission its Annual Report on Form 20-F, which included audited financial statements for the fiscal year ended March 31, 2011. The Form 20-F can be accessed by visiting the U.S. Securities and Exchange Commission's website at www.sec.gov and can also be found at the Investor Relations Section of CCBC's website at http://ir.chinacordbloodcorp.com. CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to its shareholders upon request.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
In New York: Ashley Ammon De Simone: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6583-7510
SOURCE China Cord Blood Corporation
I'm convinced the only reason this isn't higher is due to being China related. So many investors fear anything China or Asian related after being burned by all the scams out there.
You're in good company. They have quite the group of institutional holders. But, the Golden Meditech Holdings haven't been reflected yet on Yahoo.
http://finance.yahoo.com/q/mh?s=CO+Major+Holders
Golden Meditech Increase Stake in NYSE-listed Affiliate - China Cord Blood Corporation to 40.9%
Sep 28, 2011 09:10:00 (ET)
HONG KONG, Sept. 28, 2011 /PRNewswire via COMTEX/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," - 801.HK; 910801.TW), China's leading integrated healthcare enterprise, today announced that the Group has continued to increase its ownership in its NYSE-listed affiliate, China Cord Blood Corporation ("CCBC," - CO.US) from the open market. As a result of which the Group now owns 40.9% of the issued share capital of CCBC from the previous 39.5%.
CCBC is the largest cord blood banking operator in China and is the only one with multiple exclusive licenses including Beijing Municipal, Guangdong Province and Zhejiang Province, with approximately 20% stake in the exclusive operator in Shandong Province.
Mr. Kam YUEN, Chairman and Chief Executive Officer of the Group, said, "We are proud to see that CCBC has sustained strong steady growth and profitability in its initial markets in Beijing and Guangdong while continuously deliver positive news on new market expansions since its initial public offering. As the founding and largest shareholder of CCBC, we remain optimistic of CCBC's prospects in both China and Asia Pacific and are duly confident in the capability of its management team. We see considerable room for CCBC to further enhance market penetration with steady growth and market development."
Under the "one-license-per-region" regulatory framework, the government has issued seven exclusive operating licenses thus far. The strategic coverage of CCBC's current operation in Beijing, Zhejiang and Guangdong has enabled it to capture key strategic economic strongholds in the affluent eastern coastline of China.
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare devices and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx) and the Taiwan Stock Exchange (TSE). Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
Investor Relations Department
Golden Meditech Holdings Limited
Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
Tel: +852 3605 8180
Fax: +852 3605 8181
Email: ir@goldenmeditech.com
SOURCE Golden Meditech Holdings Limited
Chart is close to making a golden cross. (50 and 200 MA).
Bought 100. We'll see........
China Cord Blood Corporation Announces Participation in Upcoming Investor Conferences
http://ih.advfn.com/p.php?pid=nmona&article=49068920&symbol=CO
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will participate in the following investor conferences:
•The Morgan Stanley Global Healthcare Conference, to be held September 13-14, 2011 at the Grand Hyatt New York, and the Morgan Stanley China Healthcare Day, to be held September 15, 2011 at the Four Seasons Hotel in Boston. Management is scheduled to present and to meet with institutional investors throughout both days of both conferences.
•The UBS Global Life Sciences Conference, to be held September 19-21, 2011 at the Grand Hyatt New York. Management is scheduled to present and to meet with institutional investors throughout the first two days of the conference.
For further details, please contact your respective institutional sales representatives.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: +852-3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
In New York: Ashley Ammon De Simone: +1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6583-7510
SOURCE China Cord Blood Corporation
CO - China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
http://ih.advfn.com/p.php?pid=nmona&article=48987590&symbol=CO
Excerpt:
CO - China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=48922191&symbol=CO
China Cord Blood Corporation (NYSE: CO) ("the Company") today announced its plan to release financial results for the first quarter of fiscal year 2012 on Monday, August 29, 2011, after market close in the US.
The Company will hold a conference call at 8:00 a.m. ET on Tuesday, August 30, 2011 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 88154912.
Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company to the operator.
Supplemental financial information referenced in the conference call and the first quarter fiscal 2012 earnings press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Monday, August 29, 2011.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
In New York: Ashley De Simone: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6583-7510
SOURCE China Cord Blood Corporation
CO SEC filings & Current news:
SEC Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001467808&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
News:
http://finance.yahoo.com/q/h?s=CO+Headlines
China based equity research firm Byronic Research is initiating coverage on China Cord Blood (NYSE: CO).
We will be publishing one piece of information and related analysis every few days over the next month or so.
Using this approach, we hope to draw attention to important facts about the company without creating unnecessary volatility or hysteria. What regular readers will see over this time is a pattern of irregularities and inconsistencies that cast doubt in our minds about the current market value of the company.
We are not short sellers. We hold no position - long or short - in the company.
If you are interested in obtaining our research before it is published, please contact us or discuss here.
http://byronicre.tumblr.com
Rodman & Renshaw terminates its China Cord Blood (NYSE: CO) coverage in a research report published today. Rodman & Renshaw's last rating for China Cord Blood was a Market Outperform / Speculative Risk rating and a $6 price target.
In the report, Rodman & Renshaw states, "Effective immediately, we are terminating coverage of China Cord Blood Corp (CCBC) to better distribute resources throughout our coverage universe."
Shares of China Cord Blood closed today at $3.55, up 1.45% from Thursday's market close.
Read more: http://www.benzinga.com/analyst-ratings/analyst-color/11/07/1794677/rodman-renshaw-terminates-china-cord-blood-coverage#ixzz1T3u9KfNt
Rodman & Renshaw Terminates China Cord Blood Coverage | Benzinga.com
www.benzinga.com
Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals...
From prospectus Supplement:
http://www.sec.gov/Archives/edgar/data/1467808/000114420410058004/v201175_424b3.htm
We are the leading provider of cord blood banking services in China. We provide cord blood storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies such as cord blood transplants. We also preserve cord blood units donated by the public, provide matching services on such donated units and deliver matching units to patients in need of transplants. Our Beijing-based subsidiary, Beijing Jiachenhong Biological Technologies Co., Ltd., or Jiachenhong, was the operator of the first licensed cord blood bank in China. As a matter of policy, the PRC government only grants one cord blood banking license per province or municipality. According to a policy paper published by China’s Ministry of Health in December 2005, the PRC government intends to authorize up to ten cord blood banks. To date, it has authorized seven such licenses. Our operations currently benefit from multiple exclusive cord blood banking licenses issued in China, including our licenses for Beijing and Guangdong, and we have entered into a framework agreement to form and obtain 90% ownership in a non-wholly owned subsidiary that will become the operator of the Zhejiang Cord Blood Bank, the sole licensed cord blood bank in Zhejiang province. We also have an investment in a 19.9% equity interest in Qilu Stem Cells Engineering Company Limited, the operator of the exclusive licensed cord blood bank in Shandong province.
Our cord blood banking network is the largest in China. The aggregate number of births in Beijing, Guangdong, Zhejiang and Shandong provinces was estimated to be 2.8 million in 2008, accounting for approximately 73% of the total newborn population in the seven provinces and municipalities that have been authorized or issued cord blood banking licenses to date, according to the National Bureau of Statistics of China. We believe our leading market position and track record of growing our subscriber base position us well to continue to expand our presence in China. With a newborn population of 18.7 million in 2009, China had the second largest newborn population in the world, according to the CIA World Factbook. Cord blood banking as a precautionary healthcare measure is still a relatively new concept in China, with penetration rates that we estimate to be less than 1% of China’s overall newborn population. We expect the demand for cord blood banking services will grow significantly due to factors such as rapidly rising disposable income in the PRC, China’s one-child policy, and increasing public awareness of the benefits of cord blood and haematopoietic stem cell related therapies. Furthermore, our position as the single largest shareholder with 19.1% equity interest in CordLife Limited, or CordLife, the largest cord blood banking operator in Southeast Asia, provides the foundation for further expansion into attractive markets such as India, Indonesia and the other countries in Southeast Asia.
We have developed a highly effective sales and marketing platform that has enabled us to consistently grow our cord blood subscriber base in the markets we serve. Our 297-person sales team has direct access to expectant parents through exclusive collaboration with 220 hospitals in Beijing and Guangdong. We also cooperate with local government family planning agencies and utilize a variety of marketing programs, including media advertising, seminars and pre-natal classes, to further educate expectant parents on the benefits of cord blood banking. Our subscriber base has grown from 10,975 in March 2006 to 141,492 in June 2010.
We generate substantially all of our revenues from subscription fees. The standard payment arrangement for our services consists of processing fees payable at the time of subscription and storage fees payable by our subscribers on an annual basis for as long as the contracts remain effective, which typically have a contract period of 18 years. The contracts can be terminated early by the parents at each anniversary of the contract or further extended, at the option of the children, after reaching adulthood. This payment structure provides us with a steady stream of recurring revenue and cash flow. The proportion of our storage fee revenue increased
CO - China Cord Blood Corporation Continues Share Repurchase Program
http://ih.advfn.com/p.php?pid=nmona&article=48388318&symbol=CO
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), the first and largest cord blood banking operator in China, today announced that the Company repurchased an aggregate of 2,052,607 ordinary shares. The purchases were made at an average purchase price of $3.49 per share, for a total consideration of approximately $7.2 million between September 2010 and July 2011. The total number of shares repurchased represents approximately 47.7% of the total authorized amount under the current buyback program, which will be effective until September 30, 2011. Approximately $7.8 million still remains available for purchases under the current buyback plan.
Ms. Ting Zheng, Chairperson and CEO of CCBC, stated, "Our operational and financial performance has demonstrated consistently strong growth. As our operations continue to expand across various regions within China, we will continue to capitalize on the growing business opportunities in China to maintain this growth momentum. We strongly believe that our current market valuation has yet to reflect our growth plans and intrinsic value. Thus, the management team considers the buyback program an excellent opportunity and in the best interest of the Company and its shareholders. Moving forward, we will continue to explore various means and initiatives to add value to the Company for our shareholders."
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
In New York: Ashley Ammon De Simone: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6583-7510
SOURCE China Cord Blood Corporation
Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5%
http://ih.advfn.com/p.php?pid=nmona&article=48188059&symbol=CO
Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," - 801.HK; 910801.TW), China's leading integrated healthcare enterprise, today announced that the Group has accumulated 754,791 ordinary shares in its NYSE-listed affiliate, China Cord Blood Corporation ("CCBC," - CO.US) from the open market between December 2010 and March 2011. As a result of which the Group now owns 39.5% of the issued share capital of CCBC.
CCBC is the largest cord blood banking operator in China and is the only one with multiple exclusive operating licenses including Beijing Municipal, Guangdong Province and Zhejiang Province, with approximately 20% stake in the exclusive operator in Shandong Province. Moreover, CCBC also has a strategic interest and single largest shareholding in "Cordlife," the largest cord blood banking operator in Asia Pacific markets.
Mr. Kam YUEN, Chairman and Chief Executive Officer of the Group, said, "We are proud to see that CCBC has sustained strong steady growth and profitability in its initial markets in Beijing and Guangdong while continuously deliver positive news on new market expansions since its initial public offering. As the founding and largest shareholder of CCBC, we remain optimistic of CCBC's prospects in both China and Asia Pacific and are duly confident in the capability of its management team."
CCBC reported strong revenue growth of 29.8% at RMB340 million for the fiscal year ended March 31, 2011 and a gross margin of 77.2%, while profit attributable to shareholders increased by 86.5% at RMB91.7 million under US GAAP.
Under the "one-license-per-region" regulatory framework, the government has issued seven exclusive operating licenses thus far. The strategic coverage of CCBC's current operation in Beijing, Shangdong, Zhejiang and Guangdong has enabled it to capture four key strategic economic strongholds in the affluent eastern coastline of China, with a combined annual birth rate totaling 29 million.
Mr. Kam highlighted, "We see considerable room for CCBC to further enhance market penetration with steady growth and market development. Its potential and profitability prospects remain impressive."
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare device and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx). Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
For enquiries, please contact:
Investor Relations Department
Golden Meditech Holdings Limited
Address:
48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
Tel: +852-3605-8180
Fax: +852-3605-8181
Email: ir@goldenmeditech.com
SOURCE Golden Meditech Holdings Limited
It's a good company.
In Reply to 'mkendra'
Interesting. Looks like the best China cord blood storage play out there.
On watch list.
China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=47935298&symbol=CO
wow now co is priced higher!
It's definitely staying in the same price range.
In Reply to 'stockguy99'
dont know but its the exact same price as ccel
Anyone know why this is dropping so far today?
It's funny how news for TSX:CO ended up being linked to CO yesterday.
http://ih.advfn.com/p.php?pid=nmona&article=46938287&symbol=CO
China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=46662746&symbol=CO
SEC Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001467808&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
http://ih.advfn.com/p.php?pid=nmona&article=46563152&symbol=CO
China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company") today announced its plan to release financial results for the third quarter and first nine months of fiscal year 2011 on Monday, February 28, 2011, after market close in the US.
The Company will hold a teleconference at 8:00 p.m. ET on Monday, February 28, 2011 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the following link: http://investor.chinacordbloodcorp.com/playerlink.zhtml?c=206671&s=wm&e=3696924. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 40003001.
Supplemental financial information referenced in the conference call and the text of the third quarter press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:30 p.m. ET on the day of the conference call.
Please dial in ten minutes prior to the conference to ensure proper connection and be prepared to provide your name and company to the operator.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: +852-3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York:
Ashley M. Ammon
Tel: +1-646-277-1227
In Beijing:
Wen Lei Zheng
Tel: +86-10-6583-7510
SOURCE China Cord Blood Corporation
Correct on that. I like there growth and how they are extremely diversified. Looking towards 3/31/2011. I have a good feeling that the company is going to show terrific growth once again.
What one has to watch for here is if China loosens their current rules and allows more cord storage companies to operate in the same area. The current restrictions are very favourable to CO.
In Reply to 'necktoeye'
thanks. Took a small position today. Seems like it was the right time.
Taken from the annual, year ended March 31, 2010.
http://www.sec.gov/Archives/edgar/data/1467808/000114420410054516/v199375_20fa.htm
In Reply to 'necktoeye'
Any Idea how many units they have in storage. Thanks
Down quite a bit from the highs... very interesting considering the market for their services should be growing.
CO ... Never believe few bad bashers scam, only believe official good information. CO is undervalued now, it is going up to $4.50+ first, then move up to Target price $6.75 given by yahoo, and STRONG BUY given by AOL, Yahoo, and Google!
So, set prices higher and higher, and hold it to $4.50+ at least!
China Cord Blood Corporation Announces Completion of Warrant Exchange
http://ih.advfn.com/p.php?pid=nmona&article=45633258&symbol=CO
China Cord Blood Corporation Announces Completion of Warrant Exchange Successfully Removes 13.0 Million Warrants from Capital Structure
PR Newswire
HONG KONG, Dec. 13, 2010
HONG KONG, Dec. 13, 2010 /PRNewswire-Asia-FirstCall/ - China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), the first and largest cord blood banking operator in China, today announced the completion of its previously announced warrant exchange offer, which allowed warrant holders to receive one ordinary share for every eight warrants outstanding. The Company issued 1,627,518 ordinary shares, equivalent to 2.2% of shares outstanding as of December 10, 2010, in exchange for 13,020,236 warrants. Investors participating in the warrant exchange offer are subject to a 45-day lock up period with regard to ordinary shares acquired in the exchange offer.
Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation commented, "We believe shareholders will appreciate our simplified capital structure. With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis. With all the stakeholders' interests now fully aligned, we will continue to expand our dominance within the China market, as well as the Asia Pacific region, to better capitalize on emerging opportunities."
Immediately after giving effect to the warrant exchange, China Cord Blood Corporation will have 75,406,868 ordinary shares issued and outstanding, and any remaining warrants outstanding that are not exercised will expire at 5:00 p.m. U.S. Eastern Time on the date of this press release.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Important Additional Information
This press release and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of the Company.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York: Ashley M. Ammon: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6583-7510
SOURCE China Cord Blood Corporation
Thanks for posting the news EZ2... ;)
China Cord Blood Corporation Commences Warrant Exchange Offer
Details of Exchange Offer Provided 11/10 09:25 AM
HONG KONG, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ --China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%) ("CCBC" or "the Company"), the first and largest cord blood bank operator in China, today commenced its previously announced warrant exchange offer, and provided warrant holders with participation details. The Company will offer to exchange one ordinary share for every eight warrants. As agreed with the underwriter of the Company's recent public offering, persons receiving ordinary shares in the exchange offer agree not to offer or sell such shares until the 46th day after the consummation of the exchange offer. The warrant exchange tender offer will continue for a period of at least 20 business days starting from November 10, 2010, and is scheduled to expire on December 10, 2010, at 5:00pm United States Eastern Time.
Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%) commented, "Our warrant exchange offer is being implemented to significantly simplify our corporate structure, reduce the potential dilutive impact of the warrants, and further align the interest among management, shareholders and warrantholders."
China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%) had approximately 13,206,231 warrants and 73,746,350 ordinary shares issued and outstanding as of November 10, 2010. The company expects to issue 1,650,778 ordinary shares in exchange for 13,206,231 warrants, representing approximately 2.2% of the total ordinary shares issued and outstanding. To participate in the exchange program, warrantholders must tender their warrants in accordance with the instructions included in the Offer Letter, no later than 5:00pm United States Eastern Time on December 10, 2010.
Ms. Ting Zheng concluded, "The past nine months marked several important milestones in our corporate development history. We are excited as our operations in Beijing and Guangdong continue to bear fruits, and our nationwide roll-up strategy also yields astonishing achievements. In conjunction with our simplified corporate structure and improved liquidity profile, we are strongly convinced that shareholders will be greatly rewarded in the long run."
About China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%)
China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%) is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Important Additional Information
The tender offer to exchange common stock for warrants referenced in this press release has been made pursuant to a Tender Offer Statement on Schedule TO, containing an exchange offer statement, and other documents relating to the tender offer ("Tender Offer Statement"), which China Cord Blood (CO:$4.1100,$-0.0495,-1.19%) filed with the SEC on November 10, 2010.
This press release and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of the Company. The exchange offer described herein has not yet been commenced. At the time the exchange offer is commenced, the Company intends to file a tender offer statement on a Schedule TO containing an offer to exchange, a letter of transmittal and other related documents with the Securities and Exchange Commission (the "SEC"). Such documents will be mailed to warrant holders of record and will also be made available for distribution to beneficial owners of warrants of the Company. The solicitation of offers to exchange warrants for ordinary shares of the Company will only be made pursuant to the offer to exchange, the letter of transmittal and related documents. Warrant holders are advised to read the offer to exchange, the letter of transmittal and all related documents, if and when such documents are filed and become available, as they will contain important information about the exchange offer and proposed warrant exchange. Security holders can obtain these documents when they are filed and become available free of charge from the SEC's website at www.sec.gov. In addition, copies of these documents and other filings containing information about the Company may be obtained, if and when available, without charge, by directing a request to China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%) , Attention: Albert Chen, Chief Financial Officer, at +852 3605 8180, or on the Company's corporate website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6599-7968
SOURCE China Cord Blood Corporation (CO:$4.1100,$-0.0495,-1.19%)
This moron just leaves the same stupid message on numerous boards.
What makes you think it goes up huge tomorrow? Are you looking for a bounce from this big drop?
In Reply to 'wcg'
CO ...a good company, a great stock, will go up huge tomorrow!
Set prices high and hold it!
Strong buy!
China Cord Blood Corporation Announces Proposed Public Offering of Ordinary Shareshttp://ih.advfn.com/p.php?pid=nmona&article=45087668&symbol=CO
China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), the first and largest cord blood bank operator in China, today announced that it intends to offer and sell its ordinary shares in an underwritten offering. Jefferies & Company, Inc. is the sole bookrunner for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company is conducting the offering pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement related to the offering is being filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement relating to these securities may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340, and at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering may only be made by means of a prospectus supplement and related base prospectus.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographic coverage and is the only cord blood bank operator in China with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Completion of the proposed offering is subject to market conditions and other factors.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In Beijing: Wen Lei Zheng: +86-10-6599-7968
SOURCE China Cord Blood Corporation
China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
http://ih.advfn.com/p.php?pid=nmona&article=44856849&symbol=CO
China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), the first and largest cord blood bank operator in China, today announced that the Company has filed an amendment to its Annual Report on Form 20-F/A, which included audited financial statements for the fiscal year ended March 31, 2010 with the U.S. Securities and Exchange Commission. The Form 20-F/A can be accessed by visiting the U.S. Securities and Exchange Commission's website at www.sec.gov and can also be found at CCBC's website at http://www.chinacordbloodcorp.com , under Investor Relations. CCBC will provide a hard copy of the Annual Report, including a complete set of audited financial statements, free of charge to any shareholder upon request.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com .
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: +852-3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York:
Ashley M. Ammon or Christine Duan
Tel: +1-646-277-1227
In Beijing:
Wen Lei Zheng
Tel: +86-10-6599-7968
SOURCE China Cord Blood Corporation
China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
http://ih.advfn.com/p.php?pid=nmona&article=44696560&symbol=CO
China Cord Blood Corporation
("CCBC" or "the Company") (NYSE: CO), the first and largest cord blood bank operator in China, today announced that since the authorization of the stock repurchase program on September 15, 2010, the Company has repurchased approximately 309,000 ordinary shares for approximately US$1.6 million through October 6, 2010 at an average price per share of US$5.32. This amount represents approximately 10.7% of the total repurchase program authorized by CCBC's Board of Directors, with approximately US$13.4 million remaining in the Company's buyback authorization for repurchase prior to September 2011.
Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation, stated, "We are committed to enhancing shareholder value, and our actions in the past weeks demonstrate our commitment to our shareholders and management's confidence in the Company's business and future prospects. We do not believe the current share price reflects the intrinsic value of the Company's business. Our expansion plan in Zhejiang province that was announced in September, together with our intention to execute the warrant exchange offer to simplify our capital structure, should contribute to a stronger earnings profile. We plan to continue to grow our existing business, and at the same time, seek opportunities to expand our business in China and the Asia Pacific region."
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance
and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Phone: +852-3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York:
Ashley M. Ammon or Christine Duan
Phone: +1-646-277-1227
In Beijing:
Wen Lei Zheng
Phone: +86-10-6599-7968
SOURCE China Cord Blood Corporation
I have multiple computers and can't open the CO site on any of them. Oddly, my cell phone opens it. lol
The only thing they all have in common is the service provider. Charter Communications. And, I have them coming out tomorrow morning. This is annoying.
Thanks for the info. ;)
Yes Karin, I can open the site in Firefox. There's Flash or HTML options. The Flash option worked with firefox. Very slow though. Might be my connection tonight
Lots of links... I haven't had time to explore yet.
www.chinacordbloodcorp.com/index.html
Corporate Overview
China Cord Blood Corporation is a life sciences enterprise dedicated to the storage of umbilical cord blood stem cells. Leveraging the rapid developments in life sciences research and the increasing popularity and continuous new developments of clinical applications using stem cells, the Company endeavors to provide umbilical cord blood storage services for parents to save cord blood stem cells on behalf of their children, in China and the Asia Pacific regions, to safeguard the lives and health of their newborns. China Cord Blood Corporation is the first cord blood bank operator approved by the Ministry of Health, the People's Republic of China, to engage in the cord blood banking business. China Cord Blood Corporation provides exclusive cord blood storage services in Beijing and the Guangdong Province. China Cord Blood Corporation is also the largest cord blood bank operator in China, and is one of the founders of the highly recognized non-profit organization - AsiaCORD (Asia Cord Blood Banks) Organization.
Has anyone seen this group? They offer a great amount of DD for the Cord Blood industry. Wanted to get your input.
http://www.facebook.com/#!/CordBloodCuresAdvocacyGroup
China Cord Blood Corporation Announces Framework Agreement Regarding Fourth License - Zhejiang Province
http://ih.advfn.com/p.php?pid=nmona&article=44377251&symbol=CO
China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), the first and largest cord blood bank operator in China today announced that the Company has entered into a framework agreement to form an indirect non-wholly owned subsidiary with the Zhejiang Provincial Blood Center. Through the new entity, the Company will obtain its fourth exclusive license to conduct private and public cord blood stem cell storage services in China. The new entity will enable CCBC to operate exclusively in the Zhejiang province, a new and previously untapped geographic area in China.
According to the framework agreement, CCBC will own 90% of the new entity via a cash investment of RMB45 million ($6.6 million). The Company's internal cash reserves will fund the investment. The remaining 10% will be satisfied by Zhejiang Provincial Blood Center and secured through the contribution of physical assets. The registration and regulatory application for the new entity will commence immediately.
Under the "One license per region policy" in China, only one cord blood bank license is granted in each province or municipality. The exclusive Zhejiang cord blood bank license represents the seventh license issued in China and it will be the first license issued since early 2008. In China, CCBC is the only cord blood operator with multiple licenses and of the seven licenses issued, CCBC owns the licenses to operate exclusively in Beijing municipality and in Guangdong province. The Company also has a 19.9% minority equity interest in the exclusive operator in Shandong province, and now will form the subsidiary to operate exclusively in the Zhejiang province.
"Our entry into Zhejiang province marks a major expansion in our nationwide coverage," said Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation. "Zhejiang province is one of the most affluent regions in China with over 520,000 new births per annum, and we expect to capitalize on this huge addressable market. Our ability to obtain the Zhejiang license speaks to our industry reputation and our leadership position. Importantly, this is an accretive transaction for us and it involves no acquisition premium as well."
Ms. Zheng continued, "We are confident that we can replicate our success in Guangdong and Beijing in the exciting Zhejiang marketplace. Upon completion, we will immediately start deploying our management resources in an effort to facilitate the establishment of advance infrastructure, early market education, and arouse public awareness of the benefits of umbilical cord blood storage."
"In the meantime, we will continue to improve operational efficiency and penetration within our local markets, and to explore and evaluate new business opportunities, so that we can reward our shareholders by delivering high and sustainable growth, as well as becoming the most dominant operator in the Asia Pacific region."
Audio Webcast
The Company will hold a teleconference at 9:30 p.m. ET on Wednesday, September 15, 2010 to give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the following link: http://investor.chinacordbloodcorp.com/playerlink.zhtml?c=206671&s=wm&e=336868 6. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-866-586-2813 for US callers or +852-800-965808 for Hong Kong callers, access code: 11204994.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses available as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com .
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: +852-3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York:
Ashley M. Ammon or Christine Duan
Tel: +1-646-277-1227
In Beijing:
Wen Lei Zheng
Tel: +86-10-6599-7968
SOURCE China Cord Blood Corporation
China Cord Blood Corporation to Launch Warrant Exchange Offer
http://ih.advfn.com/p.php?pid=nmona&article=44341124&symbol=CO
China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its intention to conduct a share exchange with all existing warrant holders, in which the Company will offer to exchange one ordinary share for every eight warrants.
Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation commented, "The proposed exchange offer will streamline and simplify our shareholding structure as well as corporate structure."
China Cord Blood Corporation had approximately 13,202,731 warrants and 67,039,796 ordinary shares issued and outstanding as of September 10, 2010. The proposed exchange offer should significantly reduce the potential dilutive effect, while also removing the significant equity overhang associated with the warrants. Details of the exchange offer are expected to be available shortly.
Ms. Ting Zheng further commented, "We strive to be a responsible public company. As we focus on delivering solid operational and financial performance, we will not overlook the interests of our shareholders. The proposed exchange offer is a balanced approach to ensure that the interests of our Company, our shareholders and warrant holders are all aligned."
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses have been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com .
Important Information
This press release and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of the Company. The exchange offer described herein has not yet been commenced. At the time the exchange offer is commenced, the Company intends to file a tender offer statement on a Schedule TO containing an offer to exchange, a letter of transmittal and other related documents with the Securities and Exchange Commission (the "SEC"). Such documents will be mailed to warrant holders of record and will also be made available for distribution to beneficial owners of warrants of the Company. The solicitation of offers to exchange warrants for ordinary shares of the Company will only be made pursuant to the offer to exchange, the letter of transmittal and related documents. Warrant holders are advised to read the offer to exchange, the letter of transmittal and all related documents, if and when such documents are filed and become available, as they will contain important information about the exchange offer and proposed warrant exchange. Security holders can obtain these documents when they are filed and become available free of charge from the SEC's website at www.sec.gov. In addition, copies of these documents and other filings containing information about the Company may be obtained, if and when available, without charge, by directing a request to China Cord Blood Corporation, Attention: Albert Chen, Chief Financial Officer, at +852 3605 8180, or on the Company's corporate website at http://www.chinacordbloodcorp.com .
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: +852-3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York:
Ashley M. Ammon or Christine Duan
Tel: +1-646-277-1227
In Beijing:
Wen Lei Zheng
Tel: +86-10-6599-7968
SOURCE China Cord Blood Corporation
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
431
|
Created
|
09/04/09
|
Type
|
Free
|
Moderators |
CHINA CORD BLOOD CORPORATION (NYSE: CO)
http://www.chinacordbloodcorp.com
Company Information:
CIK 0001467808
CHINA CORD BLOOD CORPORATION, a leading provider of cord blood banking services in China. Expectant parents pay us to process and store the cord blood of their children at birth for potential future use in medical treatment of the children or their family members. The payment structure of our contracts with subscribers enable us to enjoy a steady stream of long term cash inflows from annual storage fees. We enter into 18-year-contracts with our subscribers and charge an initial processing fee at birth and a storage fee each year. These contracts can be terminated early by the parents or further extended, at the option of the children, after the children reach adulthood. We expect annual storage fees to contribute an increasing proportion of our revenue as the number of our subscribers accumulated over the years continues to grow. In addition to our fee-based commercial services, we also preserve cord blood units donated by the public and charge fees for matching units provided for patients in need of transplants. This revenue accounts for a small percentage of our total revenue.
The PRC government authorities have been following a "one license per region" policy, allowing each licensee, including us, to operate within its own region without competition. The application process for a cord blood banking license takes several years, during which time the applicant usually incurs a substantial amount of initial investments, including constructing cord blood bank facilities to demonstrate to the government authorities that it is capable of meeting the stringent application requirements. This licensing process may deter newcomers with fewer resources and less experience from competing for licenses with established cord blood banking operators in China.
Our management team successfully pioneered the commercialization of cord blood banking services in China. Jiachenhong, our Beijing-based subsidiary with operations dating back to 2002, was the operator of the first licensed cord blood bank in China. We have also developed a hospital network consisting of over 90 major hospitals in Beijing to perform cord blood collection services for our subscribers. To expand the geographic coverage of our business, we acquired the right to operate in Guangdong through the acquisition of Nuoya in May 2007. The acquisition enabled us to significantly increase the size of the market that we can address. We believe we will be able to apply the experience we gained in our successful operation in Beijing to our more recently commenced operation in Guangdong. As of June 30, 2009, we had capacity to store approximately 645,000 additional units, and we believe we have the ability to further expand our capacity to meet the increasing market demand.
Currently, we are the sole cord blood banking licensee in Beijing and Guangdong. So far, cord blood banking licenses have been issued for only six of China's 31 regions, with another four licenses expected to be issued by 2010. We expect to continue to grow our business through existing market penetration and geographical expansion. Our existing operations cover an aggregate population of approximately 110 million, including 94 million in Guangdong, which is larger than all but 12 countries in the world. According to the National Bureau of Statistics of China, there were 1.2 million newborns in Beijing and Guangdong in 2007. As the PRC government authorities issue cord blood banking licenses in more regions, we believe that there will be significant growth opportunities in China. China has a population of approximately 1.3 billion. According to the National Bureau of Statistics of China, there were 15.9 million newborns in China in 2007, representing approximately 12.0% of newborns worldwide. In addition to the large number of newborns in China, we expect increased demand for our services to be driven by a number of factors, including increasing disposable income in urban areas; greater attention to health issues as people become more financially secure; emphasis on children under China's one-child policy; and heightened public awareness of the benefits associated with cord blood storage.
Principal activities
China Cord Blood Services Corporation (the "Company") and its subsidiaries (collectively the "Group") are principally engaged in the provision of umbilical cord blood storage and ancillary services in its cord blood banks in the People's Republic of China ("PRC"). As of March 31, 2009, the Group operates two cord blood banks in the Beijing municipality and Guangdong Province, the PRC.
The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee.
The operation of cord blood banks in the PRC is regulated by certain laws and regulations. Cord blood bank operators in the PRC are required to possess a Blood Station Operation License. The licensing process for a cord blood bank is stringent and lengthy. The Ministry of Health of the PRC and the local Departments of Health have granted Blood Station Operation Licenses to cord blood banks that provide cord blood banking services. Cord blood banks collecting cord blood units from donors and providing matching cord blood units to the public without a duly obtained Blood Station Operation License face the risk of being shut down by the government. Only six cord blood banking licenses have been issued by the authorities as of March 31, 2009, of which the Company holds two. Due to the lack of a consistent and well-developed regulatory framework, operation in the cord blood banking industry in the PRC involves significant ambiguities, uncertainties and risks. The industry is highly regulated and any unilateral changes in regulations by the authorities may have a significant adverse impact on the Group's results of operations.
SEC Filings:
-------------------
Considerations:
Insider Buys:
SEC Transaction Summary - Last 6 Months - last checked April 17, 2010
Latest News:
http://finance.yahoo.com/q/h?s=CO+Headlines
List of Subsidiaries:
Exhibit 21.1 from F-1/A filed 11.18.09
http://www.sec.gov/Archives/edgar/data/1467808/000114420409052921/v161765_ex21-1.htm
China Cord Blood Services Corporation | Cayman Islands |
China Stem Cells Holdings Limited | Cayman Islands |
Beijing Jiachenhong Biological Technologies Co., Limited | PR China |
China Stem Cells (South) Company Limited | British Virgin Islands |
Guangzhou Municipality Tianhe Nuoya Bio-engineering Co. Ltd. | China |
China Stem Cells (East) Company Limited | British Virgin Islands |
19 November 2009 China Cord Blood Corp. NYSE Euronext Opening Bell
http://www.youtube.com/watch?v=OesNVlIo6xg
Transfer Agent:
Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York 10004
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |